Trump sends messages to pharmaceutical executives who are calling for drugs to reduce drug prices

President Donald Trump says Americans pay a lot against prescribed medications, and demands change.

Send 17 messages to the CEOs of the Pharmaceutical Company Thursday, saying that he will only accept an obligation that provides an immediate relief from “largely enlarged drug prices.”

The president wants other rich countries to help bearing the cost of research and developing branded drugs that can help reduce the price of these drugs.

“The days of foreign countries from the United States of America have ended at the moment when President Trump took office,” White House spokesman Kush Desi Fox Business told the exclusive.

“The Americans are only 5 % of the world’s population, but they finance 75 % of the profits of pharmaceutical companies, all because Americans are bore several times on the same micro -drugs enjoyed by people in other wealthy countries.

“President Trump has pledged to reduce drug prices for ordinary Americans, and the administration takes historical measures to ensure that the pharmaceutical companies will make the wealthy countries pay their fair share instead of continuing to tear the American people.”

HHS SEC Robert F Kennedy Jr: American patients pay more so that others can pay less – stop now

Speak exclusively to Fox Business in a recent interview, Astrazeneca CEO Pascal Soreriot said he agreed with Trump.

“For many years, the United States was covering the cost of research and development in our industry. It is very important, of course, this drug saves lives,” Soreut said. “American patients benefit first in front of anyone else in the world. This industry creates a lot of good functions. Therefore, America gets benefits from this.

“However, at some point, this cost of research and development must be shared somewhat across the rich countries. I am talking about rich countries, as in Europe or Japan, which has enough GDP to finance these. So, I completely support the idea that there is some price equation that may be modified by the gross domestic product between countries.”

index	protection	last	Changing	% Change
Tin	Astrazeneca PLC	73.09	-3.50	-4.57 %

Pharma Giant, which treats its higher drugs for diabetes and cancer among other diseases, has announced an investment of $ 50 billion over the next five years in the United States.

Astrazeneca to invest 50 billion dollars in us

The Trump administration plans to use power under the office of the American Trade Representative and the Ministry of Commerce to monitor the progress of the drug re -balance. White House officials hope that this is a cooperative effort with pharmaceutical companies and likened to expanding his hand to help other countries exchange the cost burden for medicines.

These officials prefer to change the cost structure of the prescribed medicines through a voluntary process, but they say that the administration is happy to force them through a mandatory organizational process.

index	protection	last	Changing	% Change
PFE	Pfizer Inc.	23.28	-0.55	-2.31 %
To	Eli Lily and Partners.	739.77	20.34	-2.68 %
doctrine	Gilead Sciences Inc.	112.29	-2.47	-2.15 %
Amgn	Amgen Inc.	295.10	-6.27	-2.08 %

Pfizer, Eli Lilly, Merck, Gilead and AMGEN are among the companies that have received messages where the president puts four areas where pharmaceutical companies can make changes that reduce prices:

1. To extend the prices of the most preferred nation to Medicaid
2. Ensure the prices of the most preferred nation for the newly launched drugs
3. The return of increased revenues from abroad from balance to American patients
4. Providing direct distributions to the consumer or direct to the business to get rid of the middle man in order to save costs

Get Fox Business on the Go by clicking here

He said that the president has set a final date on September 29 for re -restriction or that his team is ready to help.

Fox Business’ Suzanne O’Hallran has contributed to this report.